Target intelligence / Profile preview

Non-canonical adenine nucleotide-adding RNA polymerase

Molecular classification
Enzyme, RNA polymerase
01

Overview

The non-canonical adenine nucleotide-adding RNA polymerase refers to the activity of multi-subunit, single-subunit RNA polymerases, and primases that initiate transcription by incorporating adenine nucleotide-containing metabolites, such as NAD+, NADH, FAD, CoA, and UDP-GlcNAc, as 5′ caps on RNA transcripts instead of standard NTPs. This template-dependent process occurs at the transcription start site, where the nucleotide portion of these cofactors pairs with template DNA, producing non-canonical capped RNAs (NC-RNAs) that diversify 5′ end structures in both prokaryotes and eukaryotes. These NC caps influence RNA fate by modulating stability, nuclease susceptibility, and potentially protein recruitment, expanding the epitranscriptomic regulation of gene expression beyond canonical m7G caps. While primarily studied in bacteria, NC capping has been detected in human cells, suggesting conserved mechanisms that challenge traditional views of RNA metabolism. No direct therapeutic targeting or disease associations are established, as research focuses on fundamental biology rather than drug development.

Other names
Multi-subunit RNA polymerase (with non-canonical initiation activity)Single-subunit RNA polymerase (with non-canonical initiation activity)Primase (with non-canonical initiation activity)
02

Biological functions

RNA synthesis (template-dependent transcription initiation with nucleotide analogues)Non-canonical RNA 5′ end capping (incorporation of cofactors like NAD+, FAD, CoA, UDP-GlcNAc)Gene expression regulation (via RNA stability and degradation susceptibility)

Beyond the preview

Go deeper on Non-canonical adenine nucleotide-adding RNA polymerase.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Non-canonical adenine nucleotide-adding RNA polymerase.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call